{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(12)"],"submitter":["Bilbao-Sieyro C"],"pubmed_abstract":["Advances in acute myeloid leukemia (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax. The association between BCL2 expression and patient outcome was analyzed in a series of 176 consecutive AML patients at diagnosis (Dx), post-induction (PI), complete remission (CR) and relapse (RL). Levels increased significantly at relapse (mean 1.07 PI/0.96 CR vs. 2.17 RL, p = 0.05/p = 0.03). In multivariate analysis, high BCL2-Dx were marginally associated with worse progression-free survival, while high PI levels or at CR had an independent negative impact on outcome (PI: HR 1.58, p = 0.014; CR: HR 1.96, p = 0.008). This behavior of high PI or CR BCL2 levels and increased risk was maintained in a homogeneous patient subgroup of age <70 and intermediate cytogenetic risk (PI: HR 2.44, p = 0.037; CR: HR 2.71, p = 0.049). Finally, for this subgroup, high BCL2 at relapse indicated worse overall survival (OS, HR 1.15, p = 0.05). In conclusion, high BCL2 levels PI or at CR had an independent negative impact on patient outcome. Therefore, BCL2 expression is a dynamic marker that may be useful during AML patient follow up, and BCL2 levels at PI and/or CR may influence response to anti-BCL2 therapy."],"journal":["Diagnostics (Basel, Switzerland)"],"pagination":["E1048"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7762084"],"repository":["biostudies-literature"],"pubmed_title":["BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia."],"pmcid":["PMC7762084"],"pubmed_authors":["Bilbao-Sieyro C","Florido Y","Saez MN","Santana G","Gomez-Casares MT","Gonzalez-Perez E","Cruz-Cruz N","Sanchez-Sosa S","Stuckey R","Molero Labarta T","Gonzalez Martin JM","Rodriguez-Medina C","Fernandez R"],"additional_accession":[]},"is_claimable":false,"name":"BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia.","description":"Advances in acute myeloid leukemia (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax. The association between BCL2 expression and patient outcome was analyzed in a series of 176 consecutive AML patients at diagnosis (Dx), post-induction (PI), complete remission (CR) and relapse (RL). Levels increased significantly at relapse (mean 1.07 PI/0.96 CR vs. 2.17 RL, p = 0.05/p = 0.03). In multivariate analysis, high BCL2-Dx were marginally associated with worse progression-free survival, while high PI levels or at CR had an independent negative impact on outcome (PI: HR 1.58, p = 0.014; CR: HR 1.96, p = 0.008). This behavior of high PI or CR BCL2 levels and increased risk was maintained in a homogeneous patient subgroup of age <70 and intermediate cytogenetic risk (PI: HR 2.44, p = 0.037; CR: HR 2.71, p = 0.049). Finally, for this subgroup, high BCL2 at relapse indicated worse overall survival (OS, HR 1.15, p = 0.05). In conclusion, high BCL2 levels PI or at CR had an independent negative impact on patient outcome. Therefore, BCL2 expression is a dynamic marker that may be useful during AML patient follow up, and BCL2 levels at PI and/or CR may influence response to anti-BCL2 therapy.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2024-10-17T21:20:22.456Z","creation":"2021-02-20T16:48:43Z"},"accession":"S-EPMC7762084","cross_references":{"pubmed":["33291851"],"doi":["10.3390/diagnostics10121048"]}}